ERBB2 and breast cancer: Moreover, in vitro and in vivo data suggest that ERBB2-mutated breast cancer are sensitive to neratinib (irreversible anti-HER2 TKI) [27] and that ERBB2-mutated colon cancers are more sensitive to dual HER2 inhibition (TKI + Mab) compared to monotherapy or reversible TKI [16, 17].